Method and analytical system for performing fibrinogen assays accurately, rapidly and simply using a rotating magnetic field
First Claim
Patent Images
1. A method of performing a quantitative fibrinogen assay, comprising:
- (i) contacting a dry reagent matrix, comprised of thrombin and in which is homogeneously embedded a plurality of magnetic particles, contained in a reaction chamber and subjected to a rotating magnetic field generated by a process comprising spinning a north pole and a south pole of a magnetic field about a central point, with an amount of a diluted blood sample sufficient to fill said reaction chamber, thereby freeing said magnetic particles to move under the influence of the rotating magnetic field;
(ii) optically monitoring the response of said magnetic particles to said rotating magnetic field, during clotting of said blood sample, generating a response curve relating clotting time to fibrinogen concentration;
(iii) determining a clotting time endpoint from said response curve; and
(iv) comparing the clotting time endpoint from step (iii) to a stored standard calibration curve relating clotting time endpoint to fibrinogen content, prepared with samples of known fibrinogen content, to determine the amount of clottable fibrinogen in the sample.
2 Assignments
0 Petitions
Accused Products
Abstract
A method of performing a quantitative fibrinogen assay is provided which uses a dry reagent chemistry in combination with a rotational magnetic field and which has excellent correlation with the Fibrometer, the gold standard in the industry. Additionally, an apparatus for conducting the assay, a qualitative fibrinogen assay and a method for preparing a calibration curve for use with the quantitative fibrinogen assay are provided.
-
Citations
26 Claims
-
1. A method of performing a quantitative fibrinogen assay, comprising:
-
(i) contacting a dry reagent matrix, comprised of thrombin and in which is homogeneously embedded a plurality of magnetic particles, contained in a reaction chamber and subjected to a rotating magnetic field generated by a process comprising spinning a north pole and a south pole of a magnetic field about a central point, with an amount of a diluted blood sample sufficient to fill said reaction chamber, thereby freeing said magnetic particles to move under the influence of the rotating magnetic field; (ii) optically monitoring the response of said magnetic particles to said rotating magnetic field, during clotting of said blood sample, generating a response curve relating clotting time to fibrinogen concentration; (iii) determining a clotting time endpoint from said response curve; and (iv) comparing the clotting time endpoint from step (iii) to a stored standard calibration curve relating clotting time endpoint to fibrinogen content, prepared with samples of known fibrinogen content, to determine the amount of clottable fibrinogen in the sample. - View Dependent Claims (2, 3, 4, 5, 6)
-
-
7. An apparatus for performing a fibrinogen assay comprising:
-
(i) a reaction slide bearing a sample well for receiving a liquid sample and a reaction chamber containing a dry reagent matrix comprising thrombin and in which is embedded a plurality of magnetic particles distributed homogeneously therethrough, said sample well and reaction chamber being in fluid connection through a transport zone of geometry such that a volume of liquid analyte sample placed in said sample well and corresponding to the volume of said reaction chamber is transported from said sample well to said reaction chamber; (ii) providing a rotating magnetic field generated by a process comprising spinning a north pole and a south pole of a magnetic field about a central point (iii) an optical detection means for detecting a response of said magnetic particles to said rotating magnetic field. - View Dependent Claims (8, 9, 10, 11, 12, 13)
-
-
14. A method of performing a thrombin clotting time test, comprising:
-
(i) contacting a dry reagent matrix comprised of thrombin and in which is homogeneously embedded a plurality of magnetic particles, contained in a reaction chamber and subjected to a rotating magnetic field generated by a process comprising spinning a north pole and a south pole of a magnetic field about a central point, with an amount of an undiluted blood sample sufficient to fill said reaction chamber, thereby freeing said magnetic particles to move under the influence of the rotating magnetic field; (ii) optically monitoring the response of said magnetic particles to said rotating magnetic field, during clotting of said blood sample, to generate a response curve; and (iii) determining a thrombin clotting time from said response curve. - View Dependent Claims (15, 16, 17, 18, 19)
-
-
20. A method for preparing a standard calibration curve for measurement of fibrinogen, comprising:
-
(i) contacting a dry reagent matrix comprised of thrombin in which is homogeneously embedded a plurality of magnetic particles, contained in a reaction chamber and subjected to a rotating magnetic field generated by a process comprising spinning a north pole and a south pole of a magnetic field about a central point, with an amount of a diluted reference sample sufficient to fill said reaction chamber, wherein said diluted reference sample contains a known quantity of fibrinogen, thereby freeing said magnetic particles to move under the influence of the rotating magnetic field; (ii) optically monitoring the response of said magnetic particles to said rotating magnetic field, during clotting of said reference sample, to generate a response curve; (iii) determining a clotting time endpoint from said response curve; (iv) repeating steps (i)-(iii) using for each clotting time determination another diluted reference sample having a known quantity of fibrinogen, wherein each additional diluted reference sample used has a different known quantity of fibrinogen from all other diluted reference samples used; and (v) plotting the clotting time endpoint for each sample on one axis of a two-dimensional plot, with the other axis being the quantity of fibrinogen in the blood samples used in steps (i)-(iv) or storing electronically data comprising said clotting time endpoint for each sample and said quantity of fibrinogen in said samples, to generate said two-dimensional plot and generating said two-dimensional plot from said electronically stored data. - View Dependent Claims (21, 22, 23, 24, 25)
-
-
26. A method of performing a quantitative fibrinogen assay, comprising:
-
(i) contacting a dry reagent matrix, comprised of thrombin and in which is homogeneously embedded a plurality of magnetic particles, contained in a reaction chamber and subjected to a rotating magnetic field substantially identical to a magnetic field generated by rotating, about a central axis, a permanent magnet having opposite pole pieces, wherein the opposite pole pieces point parallel in the same direction or point simultaneously toward or away from said central axis by an angle, θ
, of from -45°
to +45°
relative to a line extending perpendicular from said reaction slide;with an amount of a diluted blood sample sufficient to fill said reaction chamber, thereby freeing said magnetic particles to move under the influence of the rotating magnetic field; (ii) optically monitoring the response of said magnetic particles to said rotating magnetic field, during clotting of said blood sample, generating a response curve relating clotting time to fibrinogen concentration; (iii) determining a clotting time endpoint from said response curve; and (iv) comparing the clotting time endpoint from step (iii) to a stored standard calibration curve relating clotting time endpoint to fibrinogen content, prepared with samples of known fibrinogen content, to determine the amount of clottable fibrinogen in the sample.
-
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeCardiovascular Diagnostics, Inc. (PharmaNetics, Inc.)
-
Original AssigneeCardiovascular Diagnostics, Inc. (PharmaNetics, Inc.)
-
InventorsOberhardt, Bruce J.
-
Primary Examiner(s)GITOMER, RALPH J
-
Application NumberUS08/068,855Time in Patent Office1,579 DaysField of Search73/54.31, 73/864.72, 209/212-215, 356/39, 364/413.09, 422/57, 422/58, 422/61, 422/73, 422/292, 435/13, 435/305, 435/805, 435/810, 435/969, 435/970, 436/69, 436/807US Class Current435/13CPC Class CodesG01N 33/4905 Determining clotting time o...G01N 33/80 involving blood groups or b...G01N 35/0098 involving analyte bound to ...
